Information Provided By:
Fly News Breaks for February 27, 2020
ADMP
Feb 27, 2020 | 07:39 EDT
As previously reported, Dawson James analyst Jason Kolbert downgraded Adamis Pharmaceuticals to Neutral from Buy, stating that the company's recent financing took him "by surprise" and "worries" him as he doesn't understand why management would raise what he considers to be very dilutive capital if Symjepi sales were strong. Adamis "may have triggered a negative downward spiral" with the fundraising, contends Kolbert, who also notes Adamis' receipt of a complete response letter regarding their Naloxone product.
News For ADMP From the Last 2 Days
There are no results for your query ADMP